Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Integrating the dynamic and energetic fields of metabolism and development
    Editorial

    Finley, L.; Gendron, J.; Miguel-Aliaga, I.; Rutter, J.
    Development (2023)

    Fulltext@MSK | Save
  • An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma
    Review

    Firestone, R.; Lesokhin, A. M.; Usmani, S. Z.
    Blood Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Unraveling the mechanism of epichaperome modulation by zelavespib: Biochemical insights on target occupancy and extended residence time at the site of action
    Journal Article

    Sharma, S.; Joshi, S.; Kalidindi, T.; Digwal, C. S.; Panchal, P.; Lee, S. G.; Zanzonico, P.; Pillarsetty, N.; Chiosis, G.
    Biomedicines (2023)

    Fulltext@MSK | Save
  • Allogeneic CAR T cells with regulated NEF expression display immune evasion and optimized signaling
    Meeting Abstract

    Perica, K.; Mansilla-Soto, J.; Kotchetkov, I.; Sadelain, M.
    Molecular Therapy (2023)

    Fulltext@MSK | Save
  • Targeting abnormal chaperone activity in a mouse model of synucleinopathy to mitigate cognitive deficits
    Meeting Abstract

    Sandoval, R.; Novikov, V.; Attaran, A.; Durcan, T. M.; Fon, E. A.; Menon, R. S.; Everling, S.; Chiosis, G.; Bussey, T. J.; Saksida, L. M.; more...
    Journal of Neurochemistry (2023)

    Fulltext@MSK | Save
  • SETD1A function is mediated through interaction with mitotic regulators BuGZ/BUB3 in leukemia
    Meeting Abstract

    Hoshii, T.; Perlee, S.; Kikuchi, S.; Nakadai, T.; Masuda, T.; Ohtsuki, S.; Matsumoto, M.; Rahumtulla, B.; Fukuyo, M.; Cifani, P.; more...
    Experimental Hematology (2023)

    Fulltext@MSK | Save
  • RNA regulators of cellular fate
    Meeting Abstract

    Kharas, M.
    Experimental Hematology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients with relapsed/refractory multiple myeloma (RRMM): Subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: Pooled analysis from MagnetisMM Studies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; Leleu, X.; Karlin, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save